Irina Rosewater, MD
Endocrinology, Diabetes & Metabolism · New Haven, CTNPI 1477793529
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.6% of the total across 803 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 52 manufacturers, the largest accounting for just 14.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $3,885 and has fallen 70.8% since, to $1,135 in 2025.
Across 803 payments — averaging $14.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- Lilly USA, LLC$1K
- Amgen$1K
- AstraZeneca$825
- AbbVie$725
- Sanofi-aventis U.S. LLC$724
- plus $5K from 46 others
What the payments were for
- Food & beverage$11,60697%
- Education$3953%
- Gifts$130%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,014 in reported general payments places this provider in the 80th percentile of 177 endocrinology, diabetes & metabolism providers in Connecticut.
See all endocrinology, diabetes & metabolism providers in Connecticut →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 351 | $680,272 |
| JardianceEmpagliflozin | 357 | $503,502 |
| TrulicityDulaglutide | 185 | $364,029 |
| MounjaroTirzepatide | 178 | $280,266 |
| JanuviaSitagliptin Phosphate | 134 | $188,570 |
| Tresiba Flextouch U-200Insulin Degludec | 87 | $100,708 |
| FarxigaDapagliflozin Propanediol | 81 | $84,599 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 39 | $55,271 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 42 | $54,661 |
| Tresiba Flextouch U-100Insulin Degludec | 58 | $52,888 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 54 | $44,701 |
| TradjentaLinagliptin | 32 | $40,887 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 23 | $32,608 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 55 | $28,846 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 168 | $27,849 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $1,676 | $685,520366 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $1,458 | $654,542389 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr | $640 | $564,087401 claims |
| MerckJanuvia | $354 | $188,570134 claims |
| AstraZenecaFarxiga | $825 | $84,59981 claims |
| AbbVieSynthroid, Armour Thyroid | $725 | $19,807170 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $394 | $8,854710 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 177 endocrinology, diabetes & metabolism providers in Connecticut.
Other endocrinology, diabetes & metabolism in New Haven
- Ania JastreboffNew Haven$536K
- Silvio InzucchiNew Haven$461K
- Philip GoldbergNew Haven$324K
- Kevan HeroldNew Haven$261K
- Gerald ShulmanNew Haven$194K
- Karl InsognaNew Haven$68K
- Clemens BergwitzNew Haven$31K
- Richard KibbeyNew Haven$18K
- Peter TebbenNew Haven$17K
- Surani FernandoNew Haven$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.